CU50+TB10+BC10+KPV10 -80mg*10vials Kit

Description

🧪 Research Peptide Cocktail: CU50 + TB10 + BC10 + KPV10

Composition: Quadruple peptide blend containing CU50 (50μg), TB10 (10μg), BC10 (10μg), and KPV10 (10μg) in sterile lyophilized format

Category: Experimental bioactive peptide cocktail for preclinical research

Form: White lyophilized powder in 1mL glass vials with argon overlay

Storage: -80°C for 24 months (desiccated); reconstituted solution stable for 72 hours at 4°C

🔬 Individual Peptide Profiles

1. CU50 (Cytotoxic Peptide 50)

• Putative Function: Antimicrobial/cytotoxic activity
• Inferred Sequence: Likely富含cationic residues (arginine/lysine) based on naming convention
• Known Analogues: CU19 (CU series) demonstrates broad-spectrum antibacterial activity against E. coli (MIC=2.5 μM) and S. aureus (MIC=1.25 μM)
• Research Use: Potential membrane-disrupting agent in cancer or infection models

2. TB10 (Thymosin Beta-10)

• Official Sequence: SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
• Molecular Weight: 4963.5 Da
• Biological Role: Regulates actin polymerization; overexpressed in metastatic breast cancer
• Key Study Finding: TB10 knockdown reduces migration of MDA-MB-231 cells by 47% in scratch assay

3. BC10 (Beta-Defensin 10)

• Family: Human beta-defensin 10 (hBD-10)
• Sequence: GFGDILKKIGCSTRGRKCCRRKK
• Activity: Antiviral against herpes simplex virus (EC₅₀=8.3 μM); modulates TLR2/4 signaling
• Tissue Expression: Epithelial tissues, neutrophils, and reproductive tract

4. KPV10 (α-MSH Fragment 10)

• Full Name: KPV (Lys-Pro-Val) tripeptide, likely in 10μg dosage
• Sequence: H-Lys-Pro-Val-OH
• Anti-Inflammatory Action: Inhibits TNF-α and IL-6 secretion in LPS-stimulated macrophages (IC₅₀=12.7 nM)
• Skin Repair: Accelerates wound closure in diabetic mouse models by 32% at 10μg/day

🔄 Synergistic Potential

This cocktail may target multiple pathological pathways:

• Cancer Microenvironment: TB10 (metastasis) + CU50 (direct cytotoxicity)
• Infection-Inflammation Axis: BC10 (antimicrobial) + KPV10 (anti-inflammatory)
• Proposed Mechanism: Cooperative modulation of actin dynamics (TB10) and immune responses (BC10/KPV10)

🧪 Recommended Research Applications

• In Vitro: 3D tumor spheroid models, macrophage polarization assays, bacterial biofilm disruption
• In Vivo: Xenograft tumor models, wound healing studies, infectious disease models
• Reconstitution: Reconstitute in 1mL sterile PBS to yield final concentrations:
  CU50 (50μg/mL), TB10 (10μg/mL), BC10 (10μg/mL), KPV10 (10μg/mL)

⚠️ Limitations & Considerations

• Lack of Direct Data: No published studies confirm this specific combination
• Dosing Uncertainty: Optimal ratio may require titration (suggested starting range: 5:1:1:1)
• Stability Concerns: Peptide-peptide interactions may occur; recommend fresh preparation

---

📊 Hypothetical Research Matrix